New York State Common Retirement Fund
ARTV

New York State Common Retirement Fund’s Artiva Biotherapeutics ARTV Stock Holding History

New York State Common Retirement Fund’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.2K Buy
+6,100
New +$55.6K ﹤0.01% 2928
2025
Q2 		– Sell
-2,937
Closed -$8.81K – 3373
2025
Q1 		$8.81K Hold
2,937
– – ﹤0.01% 3090
2024
Q4 		$29.6K Hold
2,937
– – ﹤0.01% 2981
2024
Q3 		$45.4K Buy
+2,937
New +$34K ﹤0.01% 2896

Other funds holding ARTV

SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

New York State Common Retirement Fund's ARTV Position: Q2 2026 in Review

New York State Common Retirement Fund opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 6,100 shares worth $59.2K. The stake represents ﹤0.01% of the portfolio and ranks #2928 among its holdings. This is a return to the name: New York State Common Retirement Fund previously reported a position in ARTV as recently as Q1 2025.

New York State Common Retirement Fund first reported a position in ARTV in Q3 2024 and has held it in 4 quarters since. 5 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • New York State Common Retirement Fund held 6,100 shares of Artiva Biotherapeutics worth $59.2K as of Q2 2026.
  • Artiva Biotherapeutics was a new New York State Common Retirement Fund position in Q2 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #2928 holding.
  • New York State Common Retirement Fund first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 4 quarters since.
  • 5 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.